# Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

> **NCT00220285** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 45 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Low-Grade

## Interventions

- **DRUG:** Zevalin (SH L 749 , BAY86-5128)
- **DRUG:** Zevalin (SH L 749 , BAY86-5128)

## Key facts

- **NCT ID:** NCT00220285
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220285, "Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00220285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*